Publication Name	World Journal of Clinical Oncology
Manuscript ID	96290
Country	China

Received	2024-05-02 07:06
Peer-Review Started	2024-05-02 07:06
To Make the First Decision
Return for Revision	2024-05-22 08:45
Revised	2024-06-03 07:52
Second Decision	2024-06-26 02:46
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-06-26 08:34
Articles in Press	2024-06-26 08:34
Publication Fee Transferred	2024-06-27 01:23
Edit the Manuscript by Language Editor	2024-07-03 06:08
Typeset the Manuscript	2024-07-11 03:04
Publish the Manuscript Online	2024-07-16 06:17

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Shi-Qiong Zhou, Peng Wan, Sen Zhang, Yuan Ren, Hong-Tao Li and Qing-Hua Ke
ORCID	Author(s) ORCID Number Shi-Qiong Zhou http://orcid.org/0009-0000-5619-2978 Peng Wan http://orcid.org/0009-0002-8398-6540 Sen Zhang http://orcid.org/0009-0000-6956-6326 Yuan Ren http://orcid.org/0009-0007-0995-5793 Hong-Tao Li http://orcid.org/0009-0000-2693-4993 Qing-Hua Ke http://orcid.org/0009-0003-3582-3824
Funding Agency and Grant Number
Corresponding Author	Qing-Hua Ke, MM, PhD, Additional Professor, Chief Physician, Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, No. 40 Jinglong Road, Shashi District, Jingzhou 434000, Hubei Province, China. 3803354759@qq.com
Key Words	Immunotherapy; Concurrent chemoradiotherapy; Locally advanced pancreatic adenocarcinoma; Programmed cell death 1; Sintilimab
Core Tip	The article presents an insightful exploration of a study of the combination of sintilimab with S-1 and gemcitabine concurrent radiotherapy for locally advanced pancreatic cancer (LAPC). The observation group had significantly longer median progression-free survival and overall survival than the control group. The occurrence of severe adverse events did not exhibit a statistically significant difference between the observation group and the control group, with a P value greater than 0.05. It is considered a promising, effective and well-tolerated treatment for LAPC.
Publish Date	2024-07-16 06:17
Citation	<p>Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma. <i>World J Clin Oncol</i> 2024; 15(7): 859-866</p>
URL	https://www.wjgnet.com/2218-4333/full/v15/i7/859.htm
DOI	https://dx.doi.org/10.5306/wjco.v15.i7.859

Full Article (PDF)	WJCO-15-859-with-cover.pdf
Manuscript File	96290-Review-Filipodia-check-YJP.docx
Answering Reviewers	96290-answering-reviewers.pdf
Audio Core Tip	96290-audio.mp3
Biostatistics Review Certificate	96290-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	96290-conflict-of-interest-statement.pdf
Copyright License Agreement	96290-copyright-assignment.pdf
Signed Informed Consent Form(s) or Document(s)	96290-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	96290-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	96290-non-native-speakers.pdf
Peer-review Report	96290-peer-reviews.pdf
Scientific Misconduct Check	96290-scientific-misconduct-check.png
Scientific Editor Work List	96290-scientific-editor-work-list.pdf
CrossCheck Report	96290-crosscheck-report.png
CrossCheck Report	96290-crosscheck-report.pdf